Rosacea

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Retrieved on: 
Monday, March 18, 2024
Entrepreneurship, Capsule, Patient, Food and Drug Administration, Rosacea, NDA, Red, Minocycline, Erythema, Food, Marketing, FDA, CEA, Physician, IGA, PDUFA, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.
  • The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
  • DFD-29 demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea® 40 mg capsules, and placebo for Investigator’s Global Assessment (IGA) treatment success as well as the reduction in the total inflammatory lesion count in both studies.
  • For the secondary endpoint evaluating erythema (redness) associated with rosacea, DFD-29 showed a statistically significant reduction in Clinician’s Erythema Assessment (CEA) compared to placebo in both clinical trials.”

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
Monday, March 11, 2024
American Academy of Dermatology, Microbiota, Marketing, FDA, U.S. FDA, Skin, Forehead, Entrepreneurship, Risk, AAD, Safety, GI, Red, Rosacea, Minocycline, Patient, Clinical trial, Erythema, Vagina, Microbiology, American Academy

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Unleashing The Power Of Red Light Therapy For Skincare

Retrieved on: 
Thursday, February 29, 2024
Ageing, Elasticity, Red light, Spasm, Overalls, Swelling, Skin, Cell, Skin care, Low-level laser therapy, Benefit, Health, Red, Rosacea, ATP, Dermatitis, Tissue, Light therapy, Research, Irritation, Face, Cosmetics

It is undoubtedly because of the limitless potential of Red Light therapy that leading companies such as Bestqool have launched Red Light Therapy devices that people can buy and easily use from within the comfort of their homes.

Key Points: 
  • It is undoubtedly because of the limitless potential of Red Light therapy that leading companies such as Bestqool have launched Red Light Therapy devices that people can buy and easily use from within the comfort of their homes.
  • Exploring the Benefits of Red Light Therapy for Skincare:
    It was not a long time ago that Red Light Therapy was introduced as a means of reducing pain intensity and accelerating the repair of damaged and injured tissues.
  • Incorporating Red Light Therapy into Your Skincare Routine:
    It must be heartening to know for all die-hard skincare enthusiasts that to achieve the best results related to skincare, the key is consistency.
  • Precautions and Potential Side Effects:
    On one hand, while there are several benefits and advantages of Red Light Therapy for you, there is also one side that highlights the negative side or the side effects of Red Light Therapy for the skin.

Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

Retrieved on: 
Tuesday, February 27, 2024
Investigational New Drug, Toxicology, Acne, Toxicity, Atopic dermatitis, Drug development, Skin, Risk, GLP, Safety, Human, Rosacea, IND, Pharmaceutical industry

Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.

Key Points: 
  • Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
  • There is a real need for skin disease drugs that offer high efficacy and a low risk of adverse effects with long-term use.
  • For conditions like AD, an inflammatory skin disease that affects up to 25% of babies and young children, there is a need for safer treatment options.
  • DB-007-4 is a topical multi-disease treatment that targets important pathways that play a vital role in the development of inflammatory skin diseases while being well-tolerated by skin.

Dallas Dermatology Partners Named Among D Magazine's 2023 Best Doctors

Retrieved on: 
Wednesday, February 21, 2024
University of Texas System, Private practice, Skin cancer, Psoriasis, Acne, Multimedia, Moses Austin, D Magazine, Education, University, Physician, Steven Naifeh, Baylor University Medical Center, Alpha Omega Alpha, Rosacea, Patient, Saint Louis University, Baylor College of Medicine, Stanford University, Alpha and Omega, American Academy, Research, Nursing

DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.

Key Points: 
  • DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.
  • The final list is selected by their peers, who are other practicing physicians in Dallas, and represents the most "esteemed, exceptionally skilled, and compassionate" Dallas doctors.
  • Meet the Dallas Dermatology Partners included on this year's roster.
  • Dr. Melissa Costner holds the distinction among Dallas Dermatology Partners as the doctor with the longest record— 19 years — of being named among the area's "Best Doctors" list.

La Jolla Vein & Vascular Adds New Medical Specialty; Opens Dermatology Clinic in Vista

Retrieved on: 
Thursday, February 15, 2024
Health, General Health, Skin cancer, Psoriasis, Infection, Medicine, Suite, Multimedia, MD, Moles, Venous stasis, Skin, Rash, Dermatology, UC, Varicose veins, Rosacea, Psychology, Patient, Knowledge, Dermatitis, Lipoma, Environment, Medical imaging

La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.

Key Points: 
  • La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.
  • The dermatology clinic is set to open in March, and is located at 906 Sycamore Ave, Suite 100, Vista, California.
  • View the full release here: https://www.businesswire.com/news/home/20240215088694/en/
    Dr. Heidi Busch, a board-certified dermatologist joins La Jolla Vein & Vascular to spearhead their expansion of services with a new Medical and Cosmetic Dermatology clinic in Vista, California.
  • To schedule a consultation with Dr. Busch, call 760-249-7007 or learn more about La Jolla Vein & Vascular’s services at www.ljvascular.com .